Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source

Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source Publisher Pubmed

Siavashpour Z^{1, 2} ; Aghili M³ ; Anjidani S¹ ; Zayeri F⁴ ; Moghani MM^{1, 2} ; Maleki M⁵ ; Jaberi R^{3, 6}

Show Affiliations

1. Radiotherapy Oncology Department, Shohada-e Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Clinical Research Development Unit of Shohadaye Tajrish Hospital, Tehran, Iran
3. Radiation Oncology Research Center, Iran Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
4. Proteomics Research Center and Biostatics Department, School of Allied Medical Sciences, Shahid Beheshti University of Medical Science, Tehran, Iran
5. Brachytherapy Department, Rasoul Akram Educational Hospital, Iran University of Medical Sciences, Tehran, Iran
6. Department of Physics, University of Surrey, UK, Guildford, United Kingdom

Source: Brachytherapy Published:2022

Abstract

PURPOSE: This study investigated the correlation between the prescription dose and dose to the Manchester and International Commission on Radiation Units and Measurements-report 38 (ICRU-38) lymphatic trapezoid points during high-dose-rate (HDR) brachytherapy of locally advanced cervical cancer with (Cobalt-60) 60Co. METHODS AND MATERIALS: A retrospective study was designed for; patients with locally advanced cervical cancer, treated by external beam radiotherapy and concurrent weekly Cisplatin-based chemotherapy, had no extended parametrial invasion and was treated by tandem-ovoid set, from 2017 to 2020. Groupe Europeen de Curietherapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) based target's volume, ICRU-89 revised version of Manchester points A and B, and ICRU-38 lymph node surrogate points were determined, and their dose was recorded. Paired sample t-test, linear regression analysis, and Pearson correlation analyses were done considering a statistical significance level of 0.05 and using IBM SPSS statistics (Version 23, IBM Crop.). RESULTS: Seventy-four brachytherapy cases were included. A positive and strong correlation was observed between D90 of clinical target volume (CTVHR) and points A and B dose for CTVHR〈 15 cc and 〉 35 cc. Strong and significant (p < 0.05) correlations were achieved between pelvic wall points dose and D90 and D100 of the obturator and between D50 and hot points of internal iliac lymph nodes. A strong correlation was obtained between D50 and D90 of external iliac lymph nodes and their ICRU points. CONCLUSIONS: Strong correlations were obtained between dose to the pelvic lymphatic chains and their historical ICRU-38 surrogate points during HDR brachytherapy of locally advanced cervical cancer patients with 60Co tandem-ovoid applicator sets. The correlation strength between point A and prescription dose highly depends on the CTVHR volume. © 2021 American Brachytherapy Society

Related Docs

View other Related Docs

1. Artificial Neural Network Based Gynaecological Image-Guided Adaptive Brachytherapy Treatment Planning Correction of Intra-Fractional Organs at Risk Dose Variation, Journal of Contemporary Brachytherapy (2017)

2. A Comparison of Organs at Risk Doses in Gyn Intracavitary Brachytherapy for Different Tandem Lengths and Bladder Volumes, Journal of Applied Clinical Medical Physics (2016)

3. Evaluation of Exit Skin Dose for Intra-Cavitary Brachytherapy Treatments by the Bebig 60Co Machine Using Thermoluminescent Dosimeters, Journal of Radiotherapy in Practice (2021)

4. High Dose Rate 192Ir Versus High Dose Rate 60Co Brachytherapy: An Overview of Systematic Reviews of Clinical Responses of Gynecological Cancers From 1984 to 2020, Biomedical Physics and Engineering Express (2021)

5. Evaluating Dose Distributions of High Dose Rate 60Co Brachytherapy in an Asymmetric Tumor: A Comparison of Different Designs of Vaginal Cylindrical Applicators, Applied Radiation and Isotopes (2024)

6. Knowledge Domain and Emerging Trends in Brachytherapy: A Scientometric Analysis, Precision Radiation Oncology (2022)

7. Evaluating the Utility of 3D Slicer As a Fast and Independent Tool to Assess Intrafractional Organ Dose Variations in Gynecological Brachytherapy, Brachytherapy (2016)

8. Optimum Organ Volume Ranges for Organs at Risk Dose in Cervical Cancer Intracavitary Brachytherapy, Journal of Contemporary Brachytherapy (2016)

Style	Citing Format
MLA	Siavashpour Z, et al.. "Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source." Brachytherapy, vol. 21, no. 2, 2022, pp. 158-169.
APA	Siavashpour Z, Aghili M, Anjidani S, Zayeri F, Moghani MM, Maleki M, Jaberi R (2022). Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source. Brachytherapy, 21(2), 158-169.
Chicago	Siavashpour Z, Aghili M, Anjidani S, Zayeri F, Moghani MM, Maleki M, Jaberi R. "Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source." Brachytherapy 21, no. 2 (2022): 158-169.
Harvard	Siavashpour Z et al. (2022) 'Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source', Brachytherapy, 21(2), pp. 158-169.
Vancouver	Siavashpour Z, Aghili M, Anjidani S, Zayeri F, Moghani MM, Maleki M, et al.. Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source. Brachytherapy. 2022;21(2):158-169.
BibTex	@article{ author = {Siavashpour Z and Aghili M and Anjidani S and Zayeri F and Moghani MM and Maleki M and Jaberi R}, title = {Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source}, journal = {Brachytherapy}, volume = {21}, number = {2}, pages = {158-169}, year = {2022} }
RIS	TY - JOUR AU - Siavashpour Z AU - Aghili M AU - Anjidani S AU - Zayeri F AU - Moghani MM AU - Maleki M AU - Jaberi R TI - Dose to Pelvic Lymph Nodes During Brachytherapy of Locally Advanced Cervical Cancer With 60Co Hdr Source JO - Brachytherapy VL - 21 IS - 2 SP - 158 EP - 169 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract